Merit Medical Systems, Inc. Q3 FY2025 earnings call

Martha Aronson introduced herself, discussed her background and focus since joining. Third quarter revenue and profitability exceeded expectations. Key operational highlights included U.S. commercial release of Prelude Wave, Embosphere Microspheres getting CE Mark for GAE, Scout Radar reaching 750,000 patients treated, progress with WRAPSODY-CIE commercial and reimbursement strategies, and acquisition of C2 CryoBalloon from Pentax.

Total revenue was $384.2 million, up 13% year-over-year on a GAAP basis and 12.5% on constant currency. Cardiovascular segment sales grew 13%, with Peripheral Intervention up 8% and Cardiac Intervention up 29% (excluding acquired products). Endoscopy segment grew 4%. U.S. sales increased 12% constant currency, international up 13% year-over-year. Gross profit increased ~19%, gross margin 53.6%, highest in history.

Updated 2025 guidance: GAAP net revenue growth 11%-12%, constant currency organic growth 5.9%-6.8%. Non-GAAP EPS range $3.66-$3.79. Expect to generate at least $175 million free cash flow in 2025. Fourth quarter total revenue expected to increase 7%-10.6% GAAP and 5.5%-9.1% constant currency, with non-GAAP operating margins 18.8%-20.8% and EPS $0.87-$1.01.

Risks include dynamic global macro environment, tariffs impacting gross margin, regulatory challenges like MDR, and uncertainty around new tariffs or retaliatory actions.

Q: Could you provide more color on WRAPSODY's response in the inpatient setting?

A: Martha Aronson discussed positive market response, physician training progress, and upcoming symposiums.

Q: What's the source of gross margin upside?

A: Raul Parra cited mix by product/geography, pricing improvements, and operations efforts.

Q: Thoughts on 2026 and M&A?

A: Martha Aronson focused on CGI goals and continuing to evaluate organic/inorganic growth opportunities.

Q: Softness in Endoscopy segment?

A: Raul Parra attributed to integration of acquired products and seasonality.

Q: China market dynamics?

A: Raul Parra noted softer growth due to broader macro environment but strong volume excluding OEM impacts.

Q: Details on Pentax acquisition?

A: Raul Parra and Martha Aronson discussed the product's difference, complementary nature, and potential for international expansion.